+91-8668442535

Parkinson’s Disease Therapeutics Market By Drug Class (Dopamine Agonists, Levodopa/ Caxrbidopa, Anticholinergic Drugs, Monoamine Oxidase B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT) Inhibitors and Adenosine A2 Receptor Antagonist) - Growth, Future Prospects and Competitive Analysis, 2018 – 2026

Parkinson's disease (PD) is a progressive nervous system disorder characterized by tremors, rigidity, bradykinesia, and postural instability. It is estimated that the global Parkinson's disease therapeutics market will show significant market growth over the forecast period from 2018 to 2026. Some key factors that drive PD therapeutics market growth are substantial unmet needs, the projected launch of prominent pipeline drugs (APL-130277, Accordion Pill, P2B-001, ND0612H, etc.), increase in research and development activities for the development of novel PD therapeutics and growing incidence of PD. 

The "Parkinson's Disease Therapeutics Market – Growth, Future Prospects, and Competitive Analysis, 2018 – 2026" covers a detailed PD therapeutics market from 2016 to 2026. For a comprehensive study of PD therapeutics, this market is segmented into significant drug classes such as dopamine agonists, levodopa/ caxrbidopa, anticholinergic drugs, monoamine oxidase B (MAO-B) inhibitors, catechol-O-methyltransferase (COMT) inhibitors, and adenosine A2 receptor antagonist.

To provide detailed information regarding geographical market trends and future market prospects, the global PD therapeutics market is classified based on regional markets such as North America, Europe, Latin America, Asia Pacific, the Middle East, and Africa. Furthermore, for country-level analysis, the PD therapeutics market is classified into the United States, Canada, Germany, United Kingdom, rest of Europe, Brazil, Mexico, Latin America, Japan, China, rest of Asia Pacific, GCC, and the rest of the Middle East and Africa.  

This report includes information regarding the current market trends and future market scenario for PD therapeutics; while presenting statistical data and qualitative information. For a better understanding of the ongoing trends of the PD therapeutics market and future market projections, exhaustive information about the market opportunities, drivers, and challenges in the global PD therapeutics market is included in the report. For further understanding of the R&D study and their impact on future market scenarios, pipeline analysis is included in this report, with detailed analysis and market estimation provided for phase 3 drugs. This report includes sections to provide insight into the critical players involved in the global PD therapeutics market, competitive landscape, and company profiles.  

Based on drug class, the global Parkinson's disease therapeutics market is segmented as follows:

  • Dopamine Agonists
  • Levodopa/ carbidopa
  • Anticholinergic Drugs
  • Monoamine Oxidase B (MAO-B) Inhibitors
  • Catechol-O-Methyltransferase (COMT) Inhibitors
  • Adenosine A2 Receptor Antagonist

Parkinson's disease (PD) is a nervous system disorder that affects movement; it progresses gradually and sometimes starts with a noticeable tremor. Drugs that increase dopamine levels and control non-motor symptoms are used to manage PD. Currently, dopamine receptor agonists such as pramipexole, ropinirole, Bromocriptine, rotigotine, apomorphine, etc. preferably used in the market alone or combination with levodopa/ carbidopa. Dopamine agonists are not as potent as levodopa and cause fewer dyskinesias. Levodopa, coupled with the decarboxylase inhibitor drug - carbidopa, remains the standard treatment for Parkinson's disease, which shows fewer adverse effects in short-term use. Newly approved drugs such as nouriast and preregistration phase drugs such as CVT-301 are expected to drive significant market growth during the forecast period. Furthermore, late-stage pipeline drugs such as APL-130277, Accordion Pill, P2B-001, ND0612H, etc., would facilitate market growth in the coming years.

For this study, the global Parkinson's disease therapeutics market is categorized into:

  • North America
  • United States
  • Canada
  • Europe
  • The U.K.
  • Germany
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • The Middle East and Africa
  • GCC
  • Rest of the Middle East and Africa

According to the World Health Organization (WHO), PD is a universal disorder, with a crude incidence rate of 4.5 to 19 per 100,000 population per year. According to the Parkinson's Disease Foundation, PD affects about 1 million people in the United States and more than 4 million worldwide. About 60,000 people are diagnosed each year in the United States. Among the considered geographical markets, North America is dominating the PD therapeutics market owing to some key factors, such as a higher target population pool, developed healthcare infrastructure, early diagnosis of disease, extensive research and development for novel drugs, and wide accessibility for novel therapeutics. However, Asia Pacific is set to capture a significant position in coming years because of improving healthcare infrastructure, rising treatment awareness among the general population, and growing incidence of PD. The Asia Pacific is based on an enormous population pool continually growing. Thus there is a corresponding increase in the incidence of PD that would further lead to increased demand for PD therapeutics.

Frequently asked questions :

The market for Parkinson’s Disease Therapeutics Market is expected to reach US$ XX Bn in 2026.

The Parkinson’s Disease Therapeutics Market is expected to see significant CAGR growth over the coming years, at XX%.

The report is forecasted from 2018-2026.

The base year of this report is 2021.

Abbvie, Inc., Biogen, Inc, Boehringer Ingelheim GmbH, F. Hoffman-La Roche, GlaxoSmithKline Plc., H. Lundbeck A/S, Impax Labs, Inc. are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Mar 2018
Category:  Pharmaceuticals
Report ID:   58321
Report Format:   PDF
Pages:   220
Rating:    4.4 (60)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support